NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq:XBIT) and certain of its present and former officers in the United District Court for the Western District of Texas on behalf of a class consisting of all persons or entities who purchased XBiotech securities between April 15, 2015 through November 23, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (i) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (ii) the data from 72 patients of the Phase III Study was compromised; (iii) XBiotech did not adequately sample patients to accommodate data loss; (iv) as a result of not properly sampling patients for the Phase III Study, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome; and (v) as a result of the foregoing, Defendants’ statements about its business, operations, and prospects, including statements about the Phase III Study and clinical development of Xilonix, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race
Obayashi to Acquire Multiplex in $526M Expansion Deal
US Raises Concerns Over Possible ASML EUV Machine Transfer to China
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks
Ukrainian Drone Makers Target Japan and Asia Defense Market
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 



